Ardian acquired a minority stake (approximately 20%) in Mon Veto through a primary capital increase. This "pure cash-in" operation was designed to strengthen the group's equity base without any cash-out for the founding veterinarians. The transaction supports Mon Veto's aggressive buy-and-build strategy in a rapidly consolidating European market. The partnership aims to accelerate the group's domestic expansion and facilitate its entry into highly fragmented international markets, such as Italy and Spain. The existing unitranche debt facility provided by Barings was maintained and extended to support future external growth, ensuring the group remains a top independent contender against large international corporate aggregators.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.